Sort   by:  
 Page size 
TranscriptomicsMultilineage dysplasia does not influence prognosis in patients with CEBPA mutated AML supporting the WHO proposal to classify these patients as a unique entity
By WHO 2008, CEBPA-mutated AML became a provisional subentity, but it remains to be clarified how CEBPAmut AML with multilineage dysplasia (MLD; ?50% dysplastic cells in 2-3 lineages) but no other MDS-related feature should be classified. We investigated 108 CEBPAmut AML (15.7-87.6 years) for the im...
ORGANISM(S): Homo sapiens 
2012-06-14 | E-GEOD-33223 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of Multilineage Dysplasia (MLD) in AML correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance
Full Title: Multilineage Dysplasia (MLD) in AML correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as “AML not otherwise specified” or “AML with myelodysplasia-related changes” ...
ORGANISM(S): Homo sapiens 
2011-01-01 | E-GEOD-21261 | biostudies-arrayexpress
TranscriptomicsMultilineage dysplasia and AML with mutated nucleophosmin
Multilineage dysplasia (MLD) has no impact on biological, clinico-pathological and prognostic features of AML with mutated nucleophosmin (NPM1) NPM1-mutated AML is a provisional entity in the WHO-2008 classification of myeloid neoplasms. The significance of concomitant multilineage dysplasia (MLD) i...
ORGANISM(S): Homo sapiens 
2010-07-30 | E-GEOD-18018 | biostudies-arrayexpress
Sort   by:  
 Page size